Located in Leuven, Belgium, Augustine Therapeutics is biotech company that discovers and develops innovative, best-in-class therapeutics for treating complex neurological disorders with axonal dysfunction. The company was founded in December 2019 as a spin-off from VIB and is rooted in the groundbreaking research of the VIB laboratories of Ludo Van Den Bosch, Joris de Wit, and Bart De Strooper.


Why Augustine?

The name of the company is inspired by a famous patient of the French neurologist Jean-Martin Charcot. Charcot and two other doctors were the first to identify a hereditary motor and sensory neuropathy of the peripheral nervous system that would eventually be named Charcot–Marie–Tooth (CMT) disease. CMT disease often becomes evident in young adulthood, with notable muscle weakness and loss of sensation, often accompanied by severe pain. The disease has a devastating impact on the quality of life of patients. Unfortunately, no approved therapies yet exist to treat it. Our mission is to discover innovative medicines that will transform the lives of patients suffering from complex neurological disorders, such as Charcot-Marie-Tooth disease.


The Origins

Learn more about Rob's story and the founding of Augustine in this great VIB’s article.


Robert Prior, PhD student at the VIB-KU Leuven Center for Brain & Disease Research

"As a patient, working in the Van Den Bosch lab and seeing the genesis of Augustine Therapeutics has been very special for me. It focuses on a currently untreatable disease that unfortunately runs in my family. I know the future is bright for Charcot-Marie-Tooth disease" says Rob Prior, PhD student in the Ludo Van Den Bosch lab at the VIB-KU Leuven Center for Brain & Disease Research. 


Prof. Ludo Van Den Bosch, Group leader at the VIB-KU Leuven Center for Brain & Disease Research

"This lab's pioneering research into Charcot-Marie-Tooth disease (CMT) is what led to the creation of Augustine Therapeutics. From lab to the clinic, we're working hard to develop a CMT therapy to help people like Rob and his family!​"


The Team

Gerhard Koenig, PhD - Chairman, Non Executive Director
Ward Capoen, PhD - Director
Alain Huriez, MD - Director
Erik Tambuyzer, PhD - Director
Jérôme Van Biervliet, PhD - Director
Bart Geers, PhD - Director
Sylvain Celanire, PhD - CEO & Director

Board of directors

Gerhard Koenig is a senior R&D leader with more than 28 years of experience in drug development

Board of directors

Ward Capoen is a Partner at V-Bio Ventures, which he joined in 2016

Board of directors

Alain brings over 30 years of experience in life sciences and finance

Board of directors

Dr. Erik Tambuyzer has more than 30 years of experience in human healthcare and biopharma

Board of directors

Jérôme Van Biervliet is Managing Director of VIB

Board of directors

Bart works as the investment manager for KULeuven Research & Development (LRD)

Board of directors

Sylvain has more than 20 years of experience as an executive director, entrepreneur, and advisor in the biotech/pharma sector

All our team members


Investors




thinline.be | soon production